2. Signaling Pathways
  3. Immunology/Inflammation
  4. CTLA-4

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4; CD152

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily. CTLA-4 is expressed primarily by T cells. The ligands of CTLA-4, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. The interactions of the ligands with CTLA-4 serve to inhibit T cell responses. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99540
    Tuvonralimab
    		Inhibitor 99.14%
    Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Tuvonralimab
  • HY-P990041
    Firastotug
    		Inhibitor 98.62%
    Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer.
    Firastotug
  • HY-P990048
    Muzastotug
    		Inhibitor 99.48%
    Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic.
    Muzastotug
  • HY-P99809
    Quavonlimab
    		Inhibitor ≥99.0%
    Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody.
    Quavonlimab
  • HY-P990080
    Sovipostobart
    		Inhibitor
    Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic.
    Sovipostobart
  • HY-P990945
    Tazlestobart
    		99.66%
    HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Tazlestobart
  • HY-P99760
    Nurulimab
    		Inhibitor
    Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma.
    Nurulimab
  • HY-P991139
    Futermestotug
    		Inhibitor
    Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors.
    Futermestotug
  • HY-P990739
    Evalstotug
    Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Evalstotug
  • HY-P990775
    Vilastobart
    		99.63%
    Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Vilastobart
  • HY-P991951
    ABA04
    ABA04 is an antibody against human CTLA4.
    ABA04
  • HY-P991953
    BAT4706
    BAT4706 is an antibody against human CTLA4. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).
    BAT4706
  • HY-P991961
    REGN4659
    		Inhibitor
    REGN4659 is a fully human anti-CTLA-4 monoclonal antibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice.
    REGN4659
  • HY-P991952
    ADU-1604
    		Inhibitor
    ADU-1604 is a humanized IgG1 CTLA-4 antibody. ADU-1604 binds to a unique epitope on CTLA-4 and achieves full blockade of both CD80 and CD86 interactions. ADU-1604 enhances human T cell responses. ADU-1604 demonstrates a favorable tolerability profile. ADU-1604 can be used for melanoma research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    ADU-1604
  • HY-P991958
    GIGA-564
    		Inhibitor
    GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research.
    GIGA-564
  • HY-P990848
    Anti-CTLA-4/CD152 Antibody (BN13)
    		Inhibitor
    Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV).
    Anti-CTLA-4/CD152 Antibody (BN13)
  • HY-P991566
    KD6001
    		Inhibitor
    KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer.
    KD6001
  • HY-P991775
    Anti-Rat CTLA-4 Antibody (WKH203)
    		Inhibitor
    Anti-Rat CTLA-4 Antibody (WKH203) reacts with rat CTLA-4. Anti-Rat CTLA-4 Antibody (WKH203) binds to the CTLA-4 protein disrupts the key signaling mechanisms linked to the suppression of T cell activity, triggering T cells readily and enhancing the immune system’s capacity to identify and eliminate cancer. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-Rat CTLA-4 Antibody (WKH203)
  • HY-179228
    AN02
    		Degrader
    AN02 is a derivative of Curcumin (HY-N0005). AN02 inhibits the proliferation and clonogenicity, migration and invasion of ovarian cancer cells. AN02 dose-dependently upregulates the expression of APC and mediates the degradation of CTLA-4 through SMAD4. In the small xenograft model, AN02 significantly inhibits tumor growth and reverses the tumor immune-suppressive microenvironment. AN02, when combined with Ipilimumab (HY-P9901), can enhance efficacy and inhibit epithelial-mesenchymal transition. AN02 can be used for the study of ovarian cancer.
    AN02
  • HY-P991827
    Anti-Mouse CTLA-4 Antibody (UC10-4F10-11)
    		Inhibitor
    Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) reacts with mouse cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152). Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) promotes T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305).
    Anti-Mouse CTLA-4 Antibody (UC10-4F10-11)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity